E Herrmann1, S Bierer, C Wülfing. 1. Department of Urology, University of Münster, Albert-Schweitzer Strasse 33, 48149, Münster, Germany. herrmae@ukmuenster.de
Abstract
PURPOSE: Recent advances in understanding the molecular biology of advanced and metastatic renal cell carcinoma (RCC) have led to the development of several targeted agents that show impressive antitumor efficacy. The integration of these drugs into clinical practice has revolutionized the therapeutic management of RCC. METHODS: We reviewed data on all approved targeted agents in the first-line and second-line setting, as well as, studies involving sequential therapy. Data from phase III trials are discussed, and an optional therapeutic algorithm is presented. RESULTS: Sunitinib should be used as the first-line treatment of choice for good- and intermediate-risk patients according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria, whereas temsirolimus is recommended for the poor-risk group. The combination of bevacizumab and INF-alpha can be regarded as an alternative to sunitinib. After cytokine failure, patients should be recommended to sorafenib. Everolimus must be considered after first-line failure of a tyrosine kinase inhibitor (TKI); furthermore, recent evidence suggests sequential use of TKIs before administration of everolimus. CONCLUSIONS: A range of potent drugs are available to patients with metastatic RCC. Treatment decisions should be made carefully taking into consideration that all targeted agents only have a palliative effect with prolongation of life, but do not cure metastatic RCC.
PURPOSE: Recent advances in understanding the molecular biology of advanced and metastatic renal cell carcinoma (RCC) have led to the development of several targeted agents that show impressive antitumor efficacy. The integration of these drugs into clinical practice has revolutionized the therapeutic management of RCC. METHODS: We reviewed data on all approved targeted agents in the first-line and second-line setting, as well as, studies involving sequential therapy. Data from phase III trials are discussed, and an optional therapeutic algorithm is presented. RESULTS:Sunitinib should be used as the first-line treatment of choice for good- and intermediate-risk patients according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria, whereas temsirolimus is recommended for the poor-risk group. The combination of bevacizumab and INF-alpha can be regarded as an alternative to sunitinib. After cytokine failure, patients should be recommended to sorafenib. Everolimus must be considered after first-line failure of a tyrosine kinase inhibitor (TKI); furthermore, recent evidence suggests sequential use of TKIs before administration of everolimus. CONCLUSIONS: A range of potent drugs are available to patients with metastatic RCC. Treatment decisions should be made carefully taking into consideration that all targeted agents only have a palliative effect with prolongation of life, but do not cure metastatic RCC.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels Journal: World J Urol Date: 2005-04-02 Impact factor: 4.226
Authors: Anne-Marie O'Farrell; James M Foran; Walter Fiedler; Hubert Serve; Ron L Paquette; Maureen A Cooper; Helene A Yuen; Sharianne G Louie; Heidi Kim; Susan Nicholas; Michael C Heinrich; Wolfgang E Berdel; Carlo Bello; Mark Jacobs; Paul Scigalla; William C Manning; Stephen Kelsey; Julie M Cherrington Journal: Clin Cancer Res Date: 2003-11-15 Impact factor: 12.531
Authors: Christian Eichelberg; Roman Heuer; Felix K Chun; Kristin Hinrichs; Mario Zacharias; Hartwig Huland; Hans Heinzer Journal: Eur Urol Date: 2008-08-08 Impact factor: 20.096
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Turang E Behbahani; Claudia Thierse; Claudia Baumann; Daniel Holl; Patrick J Bastian; Alexander von Ruecker; Stefan C Müller; Jörg Ellinger; Stefan Hauser Journal: World J Urol Date: 2011-10-04 Impact factor: 4.226
Authors: Montserrat Ayala-Ramirez; Cecile N Chougnet; Mouhammed Amir Habra; J Lynn Palmer; Sophie Leboulleux; Maria E Cabanillas; Caroline Caramella; Pete Anderson; Abir Al Ghuzlan; Steven G Waguespack; Desirée Deandreis; Eric Baudin; Camilo Jimenez Journal: J Clin Endocrinol Metab Date: 2012-09-10 Impact factor: 5.958